keyword
MENU ▼
Read by QxMD icon Read
search

high risk prostate cancer

keyword
https://www.readbyqxmd.com/read/28097317/surrogate-end-points-for-all-cause-mortality-in-men-with-localized-unfavorable-risk-prostate-cancer-treated-with-radiation-therapy-vs-radiation-therapy-plus-androgen-deprivation-therapy-a-secondary-analysis-of-a-randomized-clinical-trial
#1
Trevor J Royce, Ming-Hui Chen, Jing Wu, Marian Loffredo, Andrew A Renshaw, Philip W Kantoff, Anthony V D'Amico
Importance: Several surrogates for prostate cancer-specific mortality satisfying the Prentice criteria exist, but whether these are surrogates for all-cause mortality, and how their performance compares, is unknown. Objective: To ascertain and compare the performance of 4 candidate surrogates (prostate-specific antigen [PSA] failure, PSA nadir >0.5 ng/mL, PSA doubling time <9 months, and interval to PSA failure <30 months) for all-cause mortality using the proportion of treatment-effect metric...
January 12, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28097263/predicting-biochemical-recurrence-in-patients-with-high-risk-prostate-cancer-using-the-apparent-diffusion-coefficient-of-magnetic-resonance-imaging
#2
Min Young Yoon, Juhyun Park, Jeong Yeon Cho, Chang Wook Jeong, Ja Hyeon Ku, Hyeon Hoe Kim, Cheol Kwak
PURPOSE: We aimed to investigate whether the apparent diffusion coefficient (ADC) value in diffusion-weighted magnetic resonance imaging predicts the prognoses of patients with high-risk prostate cancer. MATERIALS AND METHODS: A total of 157 patients with high-risk prostate cancer (based on D'Amico's criteria) were included in the analysis. Patients underwent preoperative 3.0 Tesla magnetic resonance imaging within 2 months before radical prostatectomy. Those who received neoadjuvant hormone therapy (33 persons) or radiation therapy (18 persons) were excluded...
January 2017: Investigative and Clinical Urology
https://www.readbyqxmd.com/read/28096933/the-association-of-male-pattern-baldness-and-risk-of-cancer-and-high-grade-disease-among-men-presenting-for-prostate-biopsy
#3
Ghazi Al Edwan, Bimal Bhindi, David Margel, Karen Chadwick, Antonio Finelli, Alexandre Zlotta, John Trachtenberg, Neil Fleshner
INTRODUCTION: Androgens have been implicated in both male pattern baldness (MPB) and prostate cancer (PCa). We set out to prospectively determine if men with independently assessed MPB are at higher risk for PCa at biopsy and determine if any grade associations exist. METHODS: We prospectively enrolled 394 eligible patients presenting for prostate biopsy and independently determined their MPB pattern using the validated modified Norwood classification system (0: no balding; 1: frontal balding; 2: mild vertex balding; 3: moderate vertex balding; 4: sever vertex balding)...
November 2016: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/28096916/an-audit-of-referral-and-treatment-patterns-of-high-risk-prostate-cancer-patients-in-alberta
#4
Majed Alghamdi, Amandeep Taggar, Derek Tilley, Marc Kerba, Xanthoula Kostaras, Geoffrey Gotto, Michael Sia
INTRODUCTION: We aimed to determine the impact of clinical practice guidelines (CPG) on rates of radiation oncologist (RO) referral, androgen-deprivation therapy (ADT), radiation therapy (RT), and radical prostatectomy (RP) in patients with high-risk prostate cancer (HR-PCa). METHODS: All men >18 years, diagnosed with PCa in 2005 and 2012 were identified from the Alberta Cancer Registry. Patient age, aggregated clinical risk group (ACRG) score, Gleason score (GS), pre-treatment prostate-specific antigen (PSA), RO referral, and treatment received were extracted from electronic medical records...
November 2016: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/28096201/serum-c-peptide-total-and-high-molecular-weight-adiponectin-and-pancreatic-cancer-do-associations-differ-by-smoking
#5
Leticia M Nogueira, Christina C Newton, Michael N Pollak, Debra T Silverman, Demetrius Albanes, Satu Männistö, Stephanie J Weinstein, Eric J Jacobs, Rachael Z Stolzenberg-Solomon
BACKGROUND: Studies examining associations between circulating concentrations of C-peptide and total adiponectin, two biomarkers related to obesity and insulin secretion and sensitivity and pancreatic ductal adenocarcinoma (PDA) risk have shown inconsistent results and included limited numbers of smokers. METHODS: We examined associations of these biomarkers and high molecular weight (HMW) adiponectin with PDA, overall, and by smoking status. We conducted a pooled nested case-control analysis in 3 cohorts (Prostate, Lung, Colorectal, and Ovarian Cancer Trial, Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study, and Cancer Prevention Study-II), with 758 cases (435 current smokers) and 1052 controls (531 smokers) matched by cohort, age, sex, race, blood draw date and follow-up time...
January 17, 2017: Cancer Epidemiology, Biomarkers & Prevention
https://www.readbyqxmd.com/read/28094250/end-of-radiation-psa-as-a-novel-prognostic-factor-in-patients-undergoing-definitive-radiation-and-androgen-deprivation-therapy-for-prostate-cancer
#6
A K Narang, J Trieu, N Radwan, A Ram, S P Robertson, P He, C Gergis, E Griffith, H Singh, T A DeWeese, S Honig, A Annadanam, S Greco, C DeVille, T McNutt, T L DeWeese, D Y Song, P T Tran
BACKGROUND: In men undergoing definitive radiation for prostate cancer, it is unclear whether early biochemical response can provide additional prognostic value beyond pre-treatment risk stratification. METHODS: Prostate cancer patients consecutively treated with definitive radiation at our institution by a single provider from 1993 to 2006 and who had an end-of-radiation (EOR) PSA (n=688, median follow-up 11.2 years). We analyzed the association of an EOR PSA level, obtained during the last week of radiation, with survival outcomes...
January 17, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/28094199/risk-of-prostate-cancer-diagnosis-and-mortality-in-men-with-a-benign-initial-transrectal-ultrasound-guided-biopsy-set-a-population-based-study
#7
Nina Klemann, M Andreas Røder, J Thomas Helgstrand, Klaus Brasso, Birgitte G Toft, Ben Vainer, Peter Iversen
BACKGROUND: The risk of missing prostate cancer in the transrectal ultrasound-guided systematic biopsies of the prostate in men with suspected prostate cancer is a key problem in urological oncology. Repeat biopsy or MRI-guided biopsies have been suggested to increase sensitivity for diagnosis of prostate cancer, but the risk of disease-specific mortality in men who present with raised prostate-specific antigen (PSA) concentration and a benign initial biopsy result remains unknown. We investigated the risk of overall and prostate cancer-specific mortality in men with a benign initial biopsy set...
January 13, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28093147/re-urologist-level-correlation-in-the-use-of-observation-for-low-and-high-risk-prostate-cancer
#8
David F Penson
No abstract text is available yet for this article.
February 2017: Journal of Urology
https://www.readbyqxmd.com/read/28089917/micrornas-and-dicer1-are-regulated-by-1-25-dihydroxyvitamin-d-in-prostate-stroma
#9
Shweta Dambal, Angeline A Giangreco, Andres M Acosta, Andrew Fairchild, Zachary Richards, Ryan Deaton, Dennis Wagner, Reinhold Vieth, Peter H Gann, Andre Kajdacsy-Balla, Theodorus Van der Kwast, Larisa Nonn
Vitamin D deficiency increases the risk of lethal prostate adenocarcinomas (PCa) and the majority of older men are deficient. Although PCa arises from the epithelium, the surrounding stroma has hormonal regulatory control over the epithelium and contributes to carcinogenesis. Herein, we describe regulation of microRNAs (miRs) by the active hormone dihydroxyvitamin D (1,25(OH)2D) in human prostate stroma. 1,25(OH)2D binds the vitamin D receptor (VDR) transcription factor to regulate gene expression, including miRs, which have emerged as potent regulators of protein expression...
January 12, 2017: Journal of Steroid Biochemistry and Molecular Biology
https://www.readbyqxmd.com/read/28089387/treatment-of-men-with-high-risk-prostate-cancer-based-on-race-insurance-coverage-and-access-to-advanced-technology
#10
Robert Steven Gerhard, Dattatraya Patil, Yuan Liu, Kenneth Ogan, Mehrdad Alemozaffar, Ashesh B Jani, Omer N Kucuk, Viraj A Master, Theresa W Gillespie, Christopher P Filson
PURPOSE: We characterized factors related to nondefinitive management (NDM) of patients with high-risk prostate cancer and assessed impact from race, insurance status, and facility-level volume of technologically advanced prostate cancer treatments (i.e., intensity-modulated radiation therapy, robotic-assisted laparoscopic radical prostatectomy) on this outcome. METHODS: We identified men with high-risk localized prostate cancer (based on D׳Amico criteria) in the National Cancer Database (2010-2012)...
January 12, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28078223/testosterone-therapy-and-prostate-cancer
#11
REVIEW
Alexander W Pastuszak, Katherine M Rodriguez, Taylor M Nguyen, Mohit Khera
The use of exogenous testosterone to treat hypogonadism in the men with a history of prostate cancer (CaP) remains controversial due to fears of cancer recurrence or progression. Due to the detrimental impact of hypogonadism on patient quality of life, recent work has examined the safety of testosterone therapy (TTh) in men with a history of CaP. In this review, we evaluate the literature with regards to the safety of TTh in men with a history of CaP. TTh results in improvements in quality of life with little evidence of biochemical recurrence or progression in men with a history of CaP, or de novo cancer in unaffected men...
December 2016: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28077128/treatment-planning-comparison-of-impt-vmat-and-4%C3%AF-radiotherapy-for-prostate-cases
#12
Angelia Tran, Jingjing Zhang, Kaley Woods, Victoria Yu, Dan Nguyen, Gary Gustafson, Lane Rosen, Ke Sheng
BACKGROUND: Intensity-modulated proton therapy (IMPT), non-coplanar 4π intensity-modulated radiation therapy (IMRT), and volumetric-modulated arc therapy (VMAT) represent the most advanced treatment methods based on heavy ion and X-rays, respectively. Here we compare their performance for prostate cancer treatment. METHODS: Ten prostate patients were planned using IMPT with robustness optimization, VMAT, and 4π to an initial dose of 54 Gy to a clinical target volume (CTV) that encompassed the prostate and seminal vesicles, then a boost prescription dose of 25...
January 11, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/28077116/quality-of-life-and-functional-outcome-after-infravesical-desobstruction-and-hifu-treatment-for-localized-prostate-cancer
#13
G Hatiboglu, I V Popeneciu, M Deppert, J Nyarangi-Dix, B Hadaschik, M Hohenfellner, D Teber, S Pahernik
BACKGROUND: To evaluate quality of life, functional and oncological outcome after infravesical desobstruction and HIFU treatment for localized prostate cancer. METHODS: One hundred thirty-one patients, treated with TURP and HIFU in a single institution were followed up for oncological and functional outcome. Oncological outcome was quantified by biochemical recurrence free survival using the Stuttgart and Phoenix criteria. Quality of life was assessed by usage of standardized QLQ-C30 and QLQ-PR25 questionnaires...
January 11, 2017: BMC Urology
https://www.readbyqxmd.com/read/28075422/inflammation-cardiometabolic-markers-and-functional-changes-in-a-randomized-controlled-trial-of-a-12-month-exercise-program-for-prostate-cancer-men
#14
Katarzyna Hojan, Eliza Kwiatkowska-Borowczyk, Ewa Leporowska, Piotr Milecki
INTRODUCTION    Previous studies have shown that physical exercise in cancer patients during radiotherapy (RT) and androgen deprivation therapy (ADT) improves cardiac fitness and quality of life (QoL), and reduces fatigue but it is still not entirely known how it affects inflammation or metabolic factors and what its consequences are in prostate cancer (PCa) patients. OBJECTIVES    Effect of a 12-month physical exercise program on inflammatory and cardiometabolic factors, and on functional status in PCa patients undergoing RT and ADT...
January 10, 2017: Polskie Archiwum Medycyny Wewnętrznej
https://www.readbyqxmd.com/read/28075160/can-we-accomplish-better-oncological-results-with-robot-assisted-radical-prostatectomy
#15
Ali Riza Kural, Can Obek, Tünkut Doğanca
Surgical removal with radical prostatectomy has been a cornerstone for the treatment of prostate cancer and is associated with level one evidence for survival advantage compared to watchful waiting. Since the first structured robotic program was launched in 2000, robot-assisted radical prostatectomy (RARP) has had a rapid diffusion and surpassed its open (ORP) and laparoscopic (LRP) counterparts in the United States and is progressively expanding in other countries. Interestingly, this common acceptance of RARP was initially driven in the paucity of robust clinical evidence...
January 11, 2017: Journal of Endourology
https://www.readbyqxmd.com/read/28071611/microsomal-epoxide-hydrolase-gene-polymorphisms-and-susceptibility-to-prostate-cancer-a-systematic-review
#16
REVIEW
Dsl Srivastava
Microsomal epoxide hydrolase (mEH) is a crucial biotransformation enzyme that has capability to metabolize a large number of structurally divergent, highly reactive epoxides, and numerous environmentally exposed carcinogens. It catalyzes the conversion of xenobiotic epoxide compounds into more polar diol metabolites and may play important part of the enzymatic defense against adverse effects of foreign compounds. Most commonly, two functional polymorphisms affecting mEH enzyme activity have been identified: One in exon 3 and other in exon 4 of the mEH gene, which results in His113Tyr and Arg139His amino acid substitutions, respectively...
April 2016: Indian Journal of Cancer
https://www.readbyqxmd.com/read/28070166/biochemical-recurrence-prediction-in-high-risk-prostate-cancer-patients-following-robot-assisted-radical-prostatectomy
#17
Noriya Yamaguchi, Tetsuya Yumioka, Hideto Iwamoto, Toshihiko Masago, Shuichi Morizane, Masashi Honda, Takehiro Sejima, Atsushi Takenaka
BACKGROUND: High-risk prostate cancer treatment has been controversial. Some high-risk prostate cancer patients fail to respond to radical prostatectomy only. Thus, we aimed to investigate the predictive factors for biochemical recurrence (BCR) and identify patients who could achieve sufficient therapeutic effect by radical prostatectomy only. METHODS: Of 264 medical records reviewed, 141 low-intermediate-risk and 100 high-risk prostate cancer patients, excluding those who had received neoadjuvant hormone therapy, were analyzed...
December 2016: Yonago Acta Medica
https://www.readbyqxmd.com/read/28069853/sharp-decline-in-prostate-cancer-treatment-among-men-in-the-general-population-but-not-among-diagnosed-men
#18
Tudor Borza, Samuel R Kaufman, Vahakn B Shahinian, Phyllis Yan, David C Miller, Ted A Skolarus, Brent K Hollenbeck
The indolent nature of many prostate cancers has heightened concerns that harms from treatment may outweigh those from the disease and has resulted in a growing consensus in favor of less aggressive screening and treatment. We sought to understand the population-level impact of this consensus on the treatment of prostate cancer. Using national Medicare data for the period 2007-12, we assessed treatment rates among men with newly diagnosed prostate cancer. We identified both population-based rates (which are sensitive to changes in diagnosis and treatment patterns) and rates among diagnosed men (which are sensitive only to changes in treatment patterns)...
January 1, 2017: Health Affairs
https://www.readbyqxmd.com/read/28069053/influence-of-daily-imaging-on-plan-quality-and-normal-tissue-toxicity-for-prostate-cancer-radiotherapy
#19
Katharina Bell, Marina Heitfeld, Norbert Licht, Christian Rübe, Yvonne Dzierma
BACKGROUND: Modern radiotherapy offers various possibilities for image guided verification of patient positioning. Different clinically relevant IGRT (image guided radiotherapy) scenarios were considered with regard to their influence on dosimetric plan quality and normal tissue complication probability (NTCP). METHODS: This study is based on treatment plans of 50 prostate patients. We evaluate the clinically performed IGRT and simulate the influence of different daily IGRT scenarios on plan quality...
January 10, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/28068672/genomic-hallmarks-of-localized-non-indolent-prostate-cancer
#20
Michael Fraser, Veronica Y Sabelnykova, Takafumi N Yamaguchi, Lawrence E Heisler, Julie Livingstone, Vincent Huang, Yu-Jia Shiah, Fouad Yousif, Xihui Lin, Andre P Masella, Natalie S Fox, Michael Xie, Stephenie D Prokopec, Alejandro Berlin, Emilie Lalonde, Musaddeque Ahmed, Dominique Trudel, Xuemei Luo, Timothy A Beck, Alice Meng, Junyan Zhang, Alister D'Costa, Robert E Denroche, Haiying Kong, Shadrielle Melijah G Espiritu, Melvin L K Chua, Ada Wong, Taryne Chong, Michelle Sam, Jeremy Johns, Lee Timms, Nicholas B Buchner, Michèle Orain, Valérie Picard, Helène Hovington, Alexander Murison, Ken Kron, Nicholas J Harding, Christine P'ng, Kathleen E Houlahan, Kenneth C Chu, Bryan Lo, Francis Nguyen, Constance H Li, Ren X Sun, Richard de Borja, Christopher I Cooper, Julia F Hopkins, Shaylan K Govind, Clement Fung, Daryl Waggott, Jeffrey Green, Syed Haider, Michelle A Chan-Seng-Yue, Esther Jung, Zhiyuan Wang, Alain Bergeron, Alan Dal Pra, Louis Lacombe, Colin C Collins, Cenk Sahinalp, Mathieu Lupien, Neil E Fleshner, Housheng H He, Yves Fradet, Bernard Tetu, Theodorus van der Kwast, John D McPherson, Robert G Bristow, Paul C Boutros
Prostate tumours are highly variable in their response to therapies, but clinically available prognostic factors can explain only a fraction of this heterogeneity. Here we analysed 200 whole-genome sequences and 277 additional whole-exome sequences from localized, non-indolent prostate tumours with similar clinical risk profiles, and carried out RNA and methylation analyses in a subset. These tumours had a paucity of clinically actionable single nucleotide variants, unlike those seen in metastatic disease. Rather, a significant proportion of tumours harboured recurrent non-coding aberrations, large-scale genomic rearrangements, and alterations in which an inversion repressed transcription within its boundaries...
January 9, 2017: Nature
keyword
keyword
69231
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"